Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)

Inclusion Criteria

• •Participants are eligible to be included in the study only if all of the following criteria apply:
• •Neurologist-confirmed diagnosis of CIDP found in the medical record, with the last neurologist visit prior to enrollment containing no information that suggests this diagnosis was reversed
• •Active use of at least one of the following CIDP treatments for three months or longer, with no evidence of discontinuation of this therapy as of the last neurologist visit prior to enrollment
• •* immunoglobulin
• •* corticosteroids, with the exception of prednisone (or equivalent) monotherapy at 10mg or less per day
• •* plasma exchange
• •* efgartigimod alfa
• •* azathioprine
• •* mycophenolate mofetil
• •* cyclosporine
• •* rituximab
• •* methotrexate
• •Signed informed consent
• •Residual impairment, disability, or neurological deficits at enrollment, as defined by a raw I-RODS score of 44 or below